ILF2 and neoplasm: To evaluate whether ILF2 ASOs sensitized MM cells to DNA-damaging agents, we further treated the xenografts with NT or ILF2 ASOs every other day in combination with melphalan and evaluated tumor burden at the end of the third cycle of the combination therapy (Supplementary Fig. 1N).